The Nasdaq surged 1.95% on Monday, leading a broader market rally with the S&P 500 up 1.33% and the Dow Jones up 0.60%. This rally is fueled by gains in technology, crypto, and Greenland-related stocks amid optimism over easing U.S.-China trade tensions ahead of a key summit. Despite Chicago Fed President Austan Goolsbee's clear warning of the need for higher interest rates due to spreading inflation pressures, investors are betting on a temporary easing of geopolitical risks to sustain risk asset gains. The market's focus will remain on the outcome of the upcoming China-U.S. summit and any shifts in bond yields that could affect the Fed's rate outlook.
The Nasdaq Index's recent surge provides context for Pluang's market snapshot. For readers following technology stocks, here is Pluang's market data as of Sep 22, 2026 01:01 WIB: out of 150 priced Technology-sector US stocks tradable on Pluang, 125 rose and 25 fell today. Notable movers include AMD at USD 608.20 with a 1-day change of +8.64%, API at USD 4.34 with +8.50%, and QCOM at USD 192.45 with +8.29%.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Fannie Mae completed its 28th sale of non-performing loans, selling 919 loans totaling $203.3 million in unpaid principal to Residential Credit Opportunities Trust IX-D. The loans have an average size of $221,222 and a weighted average interest rate ...
Sergey Nazarov, co-founder of Chainlink, will speak at Sibos 2026, a major financial conference, across three sessions covering tokenized assets, intelligent money, and interoperable finance. The event, held from September 28 to October 1 in Miami Be...
SanDisk shares fell 2% while the broader memory sector, including peers Micron and Western Digital, saw gains of 3% and 0.8% respectively. This divergence occurred without any company-specific news, suggesting profit-taking or position trimming after...
A class action lawsuit has been filed against Ardelyx, Inc. for allegedly misleading investors about the commercial performance and growth prospects of its key drugs, IBSRELA and XPHOZAH, between January 2025 and August 2026. The lawsuit claims Ardel...
